KALVISTA PHARMACEUTICALS INC (KALV) Stock Fundamental Analysis
NASDAQ:KALV - Nasdaq - US4834971032 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to KALV. KALV was compared to 572 industry peers in the Biotechnology industry. While KALV has a great health rating, there are worries on its profitability. KALV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year KALV has reported negative net income.
KALV had a negative operating cash flow in the past year.
KALV had negative earnings in each of the past 5 years.
KALV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
KALV's Return On Assets of -97.24% is on the low side compared to the rest of the industry. KALV is outperformed by 75.04% of its industry peers.
KALV has a Return On Equity (-116.71%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.24% | ||
| ROE | -116.71% | ||
| ROIC | N/A |
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KALV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KALV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KALV has been increased compared to 5 years ago.
There is no outstanding debt for KALV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 2.33 indicates that KALV is not a great score, but indicates only limited risk for bankruptcy at the moment.
KALV has a better Altman-Z score (2.33) than 72.04% of its industry peers.
There is no outstanding debt for KALV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.33 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.87 indicates that KALV has no problem at all paying its short term obligations.
KALV has a Current ratio of 6.87. This is in the better half of the industry: KALV outperforms 66.55% of its industry peers.
KALV has a Quick Ratio of 6.87. This indicates that KALV is financially healthy and has no problem in meeting its short term obligations.
KALV's Quick ratio of 6.87 is fine compared to the rest of the industry. KALV outperforms 66.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.87 | ||
| Quick Ratio | 6.87 |
3. Growth
3.1 Past
KALV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.95%.
EPS 1Y (TTM)-18.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
KALV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.66% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.4%
EPS Next 2Y10.59%
EPS Next 3Y20.49%
EPS Next 5Y21.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
KALV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KALV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KALV's earnings are expected to grow with 20.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.59%
EPS Next 3Y20.49%
5. Dividend
5.1 Amount
No dividends for KALV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KALVISTA PHARMACEUTICALS INC
NASDAQ:KALV (1/30/2025, 4:30:02 PM)
After market: 8.77 0 (0%)8.77
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners111.65%
Inst Owner Change0.16%
Ins Owners1.63%
Ins Owner Change10.22%
Market Cap433.41M
Analysts87.14
Price Target28.12 (220.64%)
Short Float %17.01%
Short Ratio18.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.21%
Min EPS beat(2)1.74%
Max EPS beat(2)6.68%
EPS beat(4)2
Avg EPS beat(4)-8.9%
Min EPS beat(4)-36.67%
Max EPS beat(4)6.68%
EPS beat(8)6
Avg EPS beat(8)3.13%
EPS beat(12)10
Avg EPS beat(12)5.59%
EPS beat(16)13
Avg EPS beat(16)4.57%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.47%
PT rev (3m)-8.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.18%
EPS NY rev (1m)0%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2058.47%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.23 | ||
| P/tB | 3.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.64
EYN/A
EPS(NY)-2.64
Fwd EYN/A
FCF(TTM)-2.49
FCFYN/A
OCF(TTM)-2.48
OCFYN/A
SpS0
BVpS2.71
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.24% | ||
| ROE | -116.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 59.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.87 | ||
| Quick Ratio | 6.87 | ||
| Altman-Z | 2.33 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)129.01%
Cap/Depr(5y)89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
EPS Next Y-10.4%
EPS Next 2Y10.59%
EPS Next 3Y20.49%
EPS Next 5Y21.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.55%
OCF growth 3YN/A
OCF growth 5YN/A